Prolonged first‐line PEG‐asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol—Pharmacokinetics and antibody formation
Pediatric Blood & Cancer2017Vol. 64(12)
Citations Over TimeTop 10% of 2017 papers
Louise Tram Henriksen, Sofie Gottschalk Højfeldt, Kjeld Schmiegelow, Thomas Leth Frandsen, Peder Skov Wehner, Henrik Daa Schrøder, Birgitte Klug Albertsen, on behalf of the Nordic Society of Pediatric Hematology and Oncology, NOPHO Group
Abstract
We conclude that prolonged first-line biweekly PEG-asparaginase therapy, 1,000 IU/m²/dose was above the pharmacological target in the vast majority of patients. Presence of anti-PEG-asparaginase antibodies was not a predictor of l-asparaginase activity.
Related Papers
- → Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leukemia(2020)43 cited
- → Monitoring asparaginase activity to improve the management of patients with acute lymphoblastic leukemia: Experience in one center(2024)2 cited
- → Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study(2016)9 cited
- [Repeated treatment with L-asparaginase of acute lymphoblastic leukemia in children].(1974)
- → How do different regimens of PEG-asparaginase affect outcomes in children and adolescents with acute lymphoblastic leukemia (ALL)?(2023)